The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Supported by Plan International, the partnership will help treat over 1,000 children annually
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The standout story remains Wegovy, particularly its new oral formulation
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
